Cohance Lifesciences Limited (COHANCE) announced two proposed transactions on September 3, 2026, to strengthen its Antibody-drug Conjugate (ADC) strategy. The company plans to invest USD 13 million in NJ Bio and USD 5 million in Aruka Bio. Both transactions will be funded through internal accruals. This reorganization aims to deepen the integration of NJ Bio’s customer-facing services with Cohance and focus on developing Aruka’s proprietary pipeline through potential partnerships.

NJ Bio: Increased Ownership and Integration

Cohance will increase its common-equity ownership in NJ Bio from 56.0% to 67.3%, acquiring the entire holdings of Ms. Priyashri Nayak and the Jain Family Irrevocable Trust. Dr. Jain will retain 32.7%. Dr. Jain will continue to lead NJ Bio while also advancing Aruka’s pipeline and partnership initiatives. NJ Bio will remain focused on customer-facing contract research, development, and manufacturing services. The closer integration will combine its payload-linker and bioconjugation expertise with Cohance’s manufacturing capabilities to support customers end-to-end CRDMO development through commercial supply. This integration is expected to strengthen business performance across the combined platform over time.

Aruka Bio: Control and Development

Aruka Bio, Inc. is a private biotechnology company based in Princeton, New Jersey, focused on developing next-generation antibody-drug conjugates. Cohance’s USD 5 million equity investment will fund the buyout of other existing shareholders and convertible noteholders along with working capital. Following completion, Aruka will be owned 65% directly by Cohance, 25% by NJ Bio, and 10% by Dr. Jain. Aruka will become Cohance’s direct subsidiary. The investment consolidates control of Aruka’s proprietary ADC platform, positioning it to pursue co-development, licensing, and other collaborations with pharmaceutical and biotechnology partners as its pipeline progresses.

Umang Vohra, Executive Chairman and Group CEO, Cohance Lifesciences, said, “This reorganization gives each business a clear focus: strengthening NJ Bio’s customer offering through closer integration with Cohance and creating the opportunity for Dr Jain to lead Aruka’s next phase. This integration is expected to strengthen business performance across the combined platform over time.”

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Cohance Lifesciences Limited

Cohance Lifesciences Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Cohance moves sideways over three months, with neither buyers nor sellers taking control. Thin margins at 5.0% leave limited room for error — any demand softness or cost spike hits the bottom line hard. 1 loss quarter(s) over five years signals earnings fragility — not chronic but worth noting. Buyers show up with 4.2x the volume of sellers. Moreover, they dominated on 16 of recent sessions versus 14 for sellers — a healthy accumulation pattern. The stock rises 6.9% in three months on 18.3% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Cohance Lifesciences Limited.

Cohance Lifesciences Limited (COHANCE) breaks out, gaining +5% to ₹470.8 on the NSE on 11 Aug 2026. The stock cleared its 6M resistance trendline, transitioning from a bounce from support to a breakout. Cohance operates in the healthcare sector, specifically in specialty and generic drug manufacturing. Today’s move appears to be company-specific, driven by technical factors rather than broader sector momentum.

Technical setup — trendlines & DMA

The current 6M trendline structure shows a breakout above the resistance at ₹429.16, with the stock now trading 8.84% above this level. The 6M support trendline ends at ₹431.05, which is 8.44% below today’s price. The 50-DMA at ₹435.7 is slightly above the 200-DMA at ₹434.1, indicating a bullish trend. The stock is currently in the lower third of its 52W range of ₹266.7–₹1038.9, suggesting there may be room for further upside despite the recent breakout.

Fundamentals & business context

With a PE of 162.0 and profit margins at 5.0%, Cohance’s valuation appears stretched relative to its current earnings, especially given the revenue CAGR of 19.4%. The market may be pricing in a potential turnaround, but the declining profit CAGR of -24.2% over the past five years raises concerns. Institutional ownership stands at 23.3%, indicating some level of confidence from smart money, though the lack of recent NSE filings suggests the move is driven by technical factors rather than new fundamental information.

Algorithmic scorecard

The overall algorithmic scorecard reflects a technically strong but fundamentally weak profile. The strongest signals include the bullish trend indicated by the 50-DMA being above the 200-DMA and the bullish sentiment over the last 30 days, where up days saw significantly higher volume than down days. These factors suggest systematic accumulation and positive market sentiment. However, the weakest signals are the low profit margin of 5.0% and the negligible dividend yield of 0%, which highlight the company’s thin profits and lack of income generation for shareholders. Additionally, the company reported a loss in the last quarter, adding to the caution.

Company outlook

Cohance Lifesciences is currently navigating through a challenging phase with low revenue and EBITDA expected in Q1 FY27 due to skewed revenue schedules, increased logistics and input costs, and higher operating costs. However, the company anticipates an improvement in EBITDA in the second half of the year as volumes recover and order conversion improves. The business is expected to bottom out in Q1 FY27, with recovery becoming more visible from the second half of FY27.

Management expects Q1 FY27 to be the low point for both revenue and EBITDA, with improvement becoming visible in the second half of the year. Growth is anticipated to return from the second half of FY27 onwards, with Q2 being stable and H2 showing growth. The company plans to focus on the predictability of delivery, backed by strong quality and systems, and is progressing with a $10 million capex at the NJ Bio US facility to support future scale-up and validation readiness. Additionally, Cohance expects to spend nearly INR 3 billion in capex in FY27.

Get all details on COHANCE — P&L, peers, shareholding and more on TradeAlone.

Cohance Lifesciences Limited (COHANCE), a leading global CDMO, announced its unaudited financial results for the first quarter ended June 30, 2026. Q1FY27 reported revenue from operations of ₹4,223 million, down 23.1% year-on-year. The company’s gross margins contracted to 71.5% from 73.0% in Q1FY26, largely due to product mix and a lower contribution from the CDMO business at 38%, reflecting the lumpy nature of the business and phasing of orders towards H2.

Financial Performance

Adjusted EBITDA was ₹92 million. The reduction reflects the lower revenue base, negative operating leverage, and the impact of subsidiary consolidation. Standalone Adjusted EBITDA margins were at 9.2%. The standalone business generated revenue of ₹3,599 million and adjusted EBITDA of ₹332 million, representing a margin of 9.2%. Sapala contributed revenue of approximately ₹274 million, while NJ Bio reported revenue of ₹350 million and an adjusted EBITDA loss.

Strategic Initiatives

Mr. Umang Vohra, Executive Chairman and Group CEO, said, “As we had guided, Q1 has been weak on both revenue and EBITDA and would be our lowest quarter ever. The quarter has played out accordingly. From here, we expect improvement in Q2 and a return to year-on-year growth from the second half, supported by secured orders, scheduled deliveries, and progress across our late-stage pipeline. We have also acted on two immediate priorities: building one integrated nucleic-acid business with a clear path to full ownership of Sapala, and repositioning Agrochemicals towards an innovator-product-led portfolio. Underpinning these actions is the One Cohance culture bringing our scientific capabilities, teams, and operating practices together around common standards of safety, quality, accountability, and customer focus.”

The company’s strategic initiatives include building one integrated nucleic-acid business with clear leadership and a defined path to full ownership of Sapala. Additionally, Agrochemicals are being repositioned towards a broader innovator-product-led portfolio.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Cohance Lifesciences Limited

Cohance Lifesciences Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Cohance falls 11.4% over three months and has not found a floor yet. Thin margins at 7.9% leave limited room for error — any demand softness or cost spike hits the bottom line hard. No meaningful dividend — total return is entirely dependent on capital appreciation. The stock sits at 21% of its 52-week range, close to annual lows. Historically, value investors build positions at these levels — though cheap stocks can stay cheap. Revenue grows at 19.4% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Cohance Lifesciences Limited.